Paris (France), March 27, 2018 – PEP-Therapy, a biotechnology company which develops innovative peptides as targeted therapies for oncology, announces the presentation of preclinical data on the PEP-010 drug candidate at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place from April 14 to 18 in Chicago, USA.
Dr Sophie Lebel-Binay, Vice-President research and early clinical development at PEP-Therapy, will be presenting a poster at the AACR annual meeting in Chicago on April 17. The presentation will highlight data on PEP-010, a Cell Penetrating & Interfering Peptide. Its therapeutic properties were evaluated to demonstrate its potential as an innovative approach for breast cancers treatment.
The main preclinical results demonstrated that after PEP-010 administration, significant tumor growth inhibition is observed in patient-derived xenograft (PDX) mice models of triple-negative breast cancer and hormone-positive HER2-negative breast adenocarcinoma. Formulation and pharmacokinetic (PK) studies were conducted leading to an improvement of the stability of PEP-010 and its PK parameters. To prepare GLP toxicity studies, preliminary tolerance studies were performed on mice, rats and monkeys after repeated administration of PEP-010 without demonstrating any sign of toxicity. Antoine Prestat, CEO and co-founder of PEP-Therapy, comments “All these promising data allow to set up PEP-010 GLP toxicity studies in rodent and non-rodent species, last step before the first-in-human clinical trial”.